The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances
Despite the well-established role of human papillomavirus (HPV) as the primary cause of cervical cancer (CC) and the existence of an effective HPV vaccine, over half a million women are diagnosed with CC globally each year, with more than half of them dying from the disease. Immunotherapy has rapidl...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2025-05-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/12597 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849731636111867904 |
|---|---|
| author | Maja Pezer Naletilić Krešimir Tomić Kristina Katić Zoran Gatalica Gordan Srkalović Eduard Vrdoljak Semir Vranić |
| author_facet | Maja Pezer Naletilić Krešimir Tomić Kristina Katić Zoran Gatalica Gordan Srkalović Eduard Vrdoljak Semir Vranić |
| author_sort | Maja Pezer Naletilić |
| collection | DOAJ |
| description | Despite the well-established role of human papillomavirus (HPV) as the primary cause of cervical cancer (CC) and the existence of an effective HPV vaccine, over half a million women are diagnosed with CC globally each year, with more than half of them dying from the disease. Immunotherapy has rapidly become a cornerstone of cancer treatment, offering substantial improvements in survival rates and reducing treatment-related side effects compared to traditional therapies. For the past 25 years, chemoradiotherapy (CRT) has been the standard treatment for locally advanced CC. However, while adjuvant chemotherapy has failed to improve outcomes in locally advanced CC, the integration of neoadjuvant chemotherapy (NACT) with CRT, as well as chemoimmunoradiotherapy followed by consolidation immunotherapy, has transformed treatment strategies, demonstrating superior efficacy compared to CRT alone. In the first-line treatment of CC, adding pembrolizumab to platinum-based chemotherapy, either with or without bevacizumab, has significantly improved outcomes compared to platinum-based chemotherapy and bevacizumab alone. This review explores the current landscape of immunotherapy and biomarker advancements in CC. Furthermore, we discuss promising future directions, including the potential of personalized immunotherapy approaches and novel combination therapies to further enhance treatment efficacy and improve prognoses for patients with CC.
|
| format | Article |
| id | doaj-art-ff1950f81d5344f2b4d7d404a3db9d8c |
| institution | DOAJ |
| issn | 2831-0896 2831-090X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj-art-ff1950f81d5344f2b4d7d404a3db9d8c2025-08-20T03:08:28ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2025-05-0110.17305/bb.2025.12597The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advancesMaja Pezer Naletilić0Krešimir Tomić1Kristina Katić2https://orcid.org/0000-0001-5037-4957Zoran Gatalica3Gordan Srkalović4Eduard Vrdoljak5Semir Vranić6https://orcid.org/0000-0001-9743-7265Department of Oncology, University Hospital Center Mostar, Mostar, Bosnia and HerzegovinaDepartment of Oncology, University Hospital Center Mostar, Mostar, Bosnia and HerzegovinaDepartment of Gynecologic Oncology, University Hospital Center Zagreb, Zagreb, CroatiaReference Medicine, Phoenix, Arizona, United States of AmericaUniversity of Michigan Health-Sparrow Herbert-Herman Cancer Center, Lansing, Michigan, United States of AmericaDepartment of Oncology, University Hospital Center Split, Split, CroatiaCollege of Medicine, QU Health, Qatar University, Doha, QatarDespite the well-established role of human papillomavirus (HPV) as the primary cause of cervical cancer (CC) and the existence of an effective HPV vaccine, over half a million women are diagnosed with CC globally each year, with more than half of them dying from the disease. Immunotherapy has rapidly become a cornerstone of cancer treatment, offering substantial improvements in survival rates and reducing treatment-related side effects compared to traditional therapies. For the past 25 years, chemoradiotherapy (CRT) has been the standard treatment for locally advanced CC. However, while adjuvant chemotherapy has failed to improve outcomes in locally advanced CC, the integration of neoadjuvant chemotherapy (NACT) with CRT, as well as chemoimmunoradiotherapy followed by consolidation immunotherapy, has transformed treatment strategies, demonstrating superior efficacy compared to CRT alone. In the first-line treatment of CC, adding pembrolizumab to platinum-based chemotherapy, either with or without bevacizumab, has significantly improved outcomes compared to platinum-based chemotherapy and bevacizumab alone. This review explores the current landscape of immunotherapy and biomarker advancements in CC. Furthermore, we discuss promising future directions, including the potential of personalized immunotherapy approaches and novel combination therapies to further enhance treatment efficacy and improve prognoses for patients with CC. https://www.bjbms.org/ojs/index.php/bjbms/article/view/12597Cervical cancerCCimmunotherapyimmune checkpoint inhibitorsICIsbiomarkers |
| spellingShingle | Maja Pezer Naletilić Krešimir Tomić Kristina Katić Zoran Gatalica Gordan Srkalović Eduard Vrdoljak Semir Vranić The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances Biomolecules & Biomedicine Cervical cancer CC immunotherapy immune checkpoint inhibitors ICIs biomarkers |
| title | The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances |
| title_full | The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances |
| title_fullStr | The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances |
| title_full_unstemmed | The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances |
| title_short | The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances |
| title_sort | immunotherapy breakthroughs in cervical cancer focus on potential biomarkers and further therapy advances |
| topic | Cervical cancer CC immunotherapy immune checkpoint inhibitors ICIs biomarkers |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/12597 |
| work_keys_str_mv | AT majapezernaletilic theimmunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT kresimirtomic theimmunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT kristinakatic theimmunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT zorangatalica theimmunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT gordansrkalovic theimmunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT eduardvrdoljak theimmunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT semirvranic theimmunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT majapezernaletilic immunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT kresimirtomic immunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT kristinakatic immunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT zorangatalica immunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT gordansrkalovic immunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT eduardvrdoljak immunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances AT semirvranic immunotherapybreakthroughsincervicalcancerfocusonpotentialbiomarkersandfurthertherapyadvances |